136 related articles for article (PubMed ID: 9456189)
1. Age and left ventricular ejection fraction identify patients with advanced breast cancer at high risk for development of epirubicin-induced heart failure.
Schaadt B; Kelbaek H
J Nucl Cardiol; 1997; 4(6):494-501. PubMed ID: 9456189
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity.
Maini CL; Sciuto R; Ferraironi A; Vici P; Tofani A; Festa A; Conti F; Lopez M
J Nucl Cardiol; 1997; 4(6):502-8. PubMed ID: 9456190
[TBL] [Abstract][Full Text] [Related]
3. Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.
Basser RL; Abraham R; To LB; Fox RM; Green MD
Ann Oncol; 1999 Jan; 10(1):53-8. PubMed ID: 10076722
[TBL] [Abstract][Full Text] [Related]
4. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.
Lopez M; Vici P; Di Lauro K; Conti F; Paoletti G; Ferraironi A; Sciuto R; Giannarelli D; Maini CL
J Clin Oncol; 1998 Jan; 16(1):86-92. PubMed ID: 9440727
[TBL] [Abstract][Full Text] [Related]
5. Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.
Appel JM; Jensen BV; Nielsen DL; Ryberg M; Zerahn B
Int J Cardiovasc Imaging; 2010 Feb; 26(2):217-23. PubMed ID: 19823942
[TBL] [Abstract][Full Text] [Related]
6. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A
Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients.
Vulsteke C; Pfeil AM; Maggen C; Schwenkglenks M; Pettengell R; Szucs TD; Lambrechts D; Dieudonné AS; Hatse S; Neven P; Paridaens R; Wildiers H
Breast Cancer Res Treat; 2015 Jul; 152(1):67-76. PubMed ID: 26017071
[TBL] [Abstract][Full Text] [Related]
9. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
[TBL] [Abstract][Full Text] [Related]
10. Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.
Nielsen D; Jensen JB; Dombernowsky P; Munck O; Fogh J; Brynjolf I; Havsteen H; Hansen M
J Clin Oncol; 1990 Nov; 8(11):1806-10. PubMed ID: 2230869
[TBL] [Abstract][Full Text] [Related]
11. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients.
Jensen BV; Skovsgaard T; Nielsen SL
Ann Oncol; 2002 May; 13(5):699-709. PubMed ID: 12075737
[TBL] [Abstract][Full Text] [Related]
12. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.
Jensen BV; Nielsen SL; Skovsgaard T
Lancet; 1996 Feb; 347(8997):297-9. PubMed ID: 8569365
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
Ghasemi K; Vaseghi G; Mansourian M
J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
[TBL] [Abstract][Full Text] [Related]
14. Dexrazoxane cardioprotection in advanced breast cancer patients undergoing high-dose epirubicin treatment.
Vici P; Ferraironi A; Di Lauro L; Carpano S; Conti F; Belli F; Paoletti G; Maini CL; Lopez M
Clin Ter; 1998; 149(921):15-20. PubMed ID: 9621483
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil.
Havsteen H; Brynjolf I; Svahn T; Dombernowsky P; Godtfredsen J; Munck O
Cancer Chemother Pharmacol; 1989; 23(2):101-4. PubMed ID: 2910506
[TBL] [Abstract][Full Text] [Related]
17. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
18. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
20. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction.
Daugaard G; Lassen U; Bie P; Pedersen EB; Jensen KT; Abildgaard U; Hesse B; Kjaer A
Eur J Heart Fail; 2005 Jan; 7(1):87-93. PubMed ID: 15642537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]